KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma
Summary : MSD outside the United States and Canada, and Eisai today announced that the Japanese Ministry of Health, Labour and Welfare…